The delayed effects of phencyclidine (PCP) disrupt latent inhibition in a conditioned taste aversion paradigm

被引:31
作者
Turgeon, SM [1 ]
Auerbach, EA
Heller, MA
机构
[1] Amherst Coll, Dept Psychol, Amherst, MA 01002 USA
[2] Amherst Coll, Neurosci Program, Amherst, MA 01002 USA
关键词
latent inhibition; phencyclidine; schizophrenia;
D O I
10.1016/S0091-3057(98)00026-4
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
The acute effects of a low dose of phencyclidine (PCP) and the delayed effects of a high dose of PCP on latent inhibition (LI) were assessed in a series of experiments using conditioned taste aversion paradigms. Each paradigm involved a preexposure phase in which water-deprived male rats were allowed access to either water (nonpreexposed; NPE) or 5% sucrose (preexposed; PE), followed by a conditioning phase in which animals were allowed access to sucrose and subsequently injected with the negative reinforcer lithium chloride, and a test phase in which animals were allowed access to both sucrose and water. LI was assessed by comparing the %-sucrose consumed in PE and NPE groups on the test day. The effects of low-dose PCP (2.5 mg/kg) were assessed by comparing LI in animals treated with vehicle or PCP 15 min prior to the onset of the preexposure and conditioning phases. A 4-day paradigm involved 2 days of preexposure followed by a day of conditioning and a test day. This paradigm produced comparable levels of LI in vehicle and PCP-treated animals. A 5-day extinction paradigm involved 2 days of preexposure followed by 2 days of conditioning and a test day. This paradigm abolished LI in vehicle and PCP-treated animals. A 3-day paradigm involved 1 day of preexposure followed by a day of conditioning and a test day. One day of preexposure induced a modified LI effect in both in vehicle and PCP-treated animals. The delayed effects of high dose PCP (8.6 mg/kg) were assessed by comparing LI in animals treated with vehicle or PCP 20 h prior to the onset of the preexposure and conditioning phases in the 4-day paradigm. PCP disrupted latent inhibition in this paradigm. The results are discussed in the context of their relevance to the ability for PCP to model schizophrenic symptomatology. (C) 1998 Elsevier Science Inc.
引用
收藏
页码:553 / 558
页数:6
相关论文
共 42 条
[1]   NEUROPHYSIOLOGICAL STUDIES OF SENSORY GATING IN RATS - EFFECTS OF AMPHETAMINE, PHENCYCLIDINE, AND HALOPERIDOL [J].
ADLER, LE ;
ROSE, G ;
FREEDMAN, R .
BIOLOGICAL PSYCHIATRY, 1986, 21 (8-9) :787-798
[2]  
ALLEN RM, 1978, AM J PSYCHIAT, V135, P1081
[3]  
Angrist B, 1994, Amphetamine and Its Analogues, P387
[4]   THE DISSOCIATIVE ANESTHETICS, KETAMINE AND PHENCYCLIDINE, SELECTIVELY REDUCE EXCITATION OF CENTRAL MAMMALIAN NEURONS BY N-METHYL-ASPARTATE [J].
ANIS, NA ;
BERRY, SC ;
BURTON, NR ;
LODGE, D .
BRITISH JOURNAL OF PHARMACOLOGY, 1983, 79 (02) :565-575
[5]   OBSERVATIONS ON THE PSYCHOTOMIMETIC EFFECTS OF SERNYL [J].
BAKKER, CB ;
AMINI, FB .
COMPREHENSIVE PSYCHIATRY, 1961, 2 (05) :269-280
[6]   DIFFERENTIAL PERFORMANCE OF ACUTE AND CHRONIC-SCHIZOPHRENICS IN A LATENT INHIBITION TASK [J].
BARUCH, I ;
HEMSLEY, DR ;
GRAY, JA .
JOURNAL OF NERVOUS AND MENTAL DISEASE, 1988, 176 (10) :598-606
[7]   INTERACTIONS BETWEEN GLUTAMATERGIC AND MONOAMINERGIC SYSTEMS WITHIN THE BASAL GANGLIA - IMPLICATIONS FOR SCHIZOPHRENIA AND PARKINSONS-DISEASE [J].
CARLSSON, M ;
CARLSSON, A .
TRENDS IN NEUROSCIENCES, 1990, 13 (07) :272-276
[8]   POSITIVE AND NEGATIVE SCHIZOPHRENIC SYMPTOMS, ATTENTION, AND INFORMATION-PROCESSING [J].
CORNBLATT, BA ;
LENZENWEGER, MF ;
DWORKIN, RH ;
KIMLING, LE .
SCHIZOPHRENIA BULLETIN, 1985, 11 (03) :397-408
[9]   MESOLIMBIC AND MESOCORTICAL DOPAMINE ACTIVATION INDUCED BY PHENCYCLIDINE - CONTRASTING PATTERN TO STRIATAL RESPONSE [J].
DEUTCH, AY ;
TAM, SY ;
FREEMAN, AS ;
BOWERS, MB ;
ROTH, RH .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1987, 134 (03) :257-264
[10]   EFFECTS OF ANTIPSYCHOTIC-DRUGS ON LATENT INHIBITION - SENSITIVITY AND SPECIFICITY OF AN ANIMAL BEHAVIORAL-MODEL OF CLINICAL DRUG-ACTION [J].
DUNN, LA ;
ATWATER, GE ;
KILTS, CD .
PSYCHOPHARMACOLOGY, 1993, 112 (2-3) :315-323